Up a level |
Number of items: 1.
Duell, J, Gonzalez-Barca, E, Augustin, M, Jurczak, W, Liberati, AM, de Vos, S, Nagy, Z, Obr, A, Gaidano, G, Abrisqueta, P et al (show 11 more authors)
(2020)
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
.